Status:
TERMINATED
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Non-melanomatous Skin Cancer
Pancreatic Cancer
Eligibility:
All Genders
Brief Summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE:...
Detailed Description
OBJECTIVES: * To identify TAB3 transcript/protein as a molecular marker of cancer, specifically testicular, skin, small intestine, and pancreatic cancer. * To characterize TAB3 and its signaling netw...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Paraffin tissue blocks from surgical pathology cancer cases, specifically testicular, skin, small intestine, and pancreatic cancer, available
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- Not specified
Exclusion
Key Trial Info
Start Date :
February 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00899132
Start Date
February 1 2007
End Date
September 1 2012
Last Update
September 29 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065